| Wednesday afternoon 5 September | |
|---|---|
| 13.00–14.00 | Lunch |
| 14.00–17.45 Presymposium FENNIA II | Systemic connective tissue diseases with a focus on systemic sclerosis Kari Eklund 14.00–14.30: Challenges of systemic sclerosis in clinical practice • Roger Hesselstrand 14.30–15.00: Capillaroscopy in diagnosis and follow-up of systemic sclerosis • Pinja Parmanne |
| Coffee break | |
| 15.30–16.00: Case 1 – Denmark Presenter: Sophine Boysen Klintel, Discussant: Søren Jacobsen 16.00–16.30: Case 2 – Sweden Presenter: Heidi Kokkonen, Discussant: Bengt Wahlin | |
| Break | |
| 16.45–17.15: Case 3 – Norway Presenter: Marianne Angelshaus, Discussant: Helena Andersson 17.15–17.45: Case 4 – Finland Presenter: Pirjo Pihlajisto, Discussant: Tom Pettersson | |
| 19.00–20.30 | Get together, Restaurant Marine |
| Thursday 6 September | ||
|---|---|---|
| 9.30–11.45 | Session 1 EUROPAEA Update on synthetic and biologic therapies Pia Isomäki, Tuulikki Sokka-Isler 9.30–10.00: Methotrexate – mechanisms of action in arthritis • John Isaacs 10.00–10.30: Glucocorticoids – mechanisms of action in arthritis and joint pain • Jan Tuckermann | |
| 10.30–10.45 Coffee break and exhibition | ||
| 10.45–11.15: Clinical experience on switching to biosimilar • Tore Kvien 11.15–11.45: The clinical significance of drug level and anti-drug antibody testing in patients using biologic therapies • Sakari Jokiranta |
||
| 11.45-12.30 | Lunch and exhibition Poster session 1 (posters PP01–41) |
|
| 12.30–14.00 | Parallel session 2 EUROPAEA Burden of Rheumatoid Arthritis Johan Askling, Kari Puolakka 12.30–13.00: Cardiovascular disease and rheumatoid arthritis • Anne Grete Semb 13.00–13.30: Malignancies and rheumatoid arthritis • Johan Askling 13.30–14.00: Costs and rheumatoid arthritis • Vappu Rantalaiho |
Parallel session 3 FENNIA I Lymphocyte responses in autoimmune diseases Meliha Kapetanovic, Marjatta Leirisalo-Repo 12.30–13.00: Abnormal vaccination responses in Sjögren’s syndrome • Marie Wahren-Herlenius 13.00–13.30: Somatic mutations in cytotoxic T lymphocytes in rheumatoid arthritis • Satu Mustjoki 13.30–14.00: Abnormal STAT activity in lymphoid cells in autoimmune diseases • Pia Isomäki |
| 14.00–14.30 | Coffee break and exhibition Guided poster tours 1 and 2 |
Tour 1: Basic science, Chair Katriina Vuolteenaho, Finland (PP03, PP09, PP10, PP23) Tour 2: Arthritis, Chair Silje Syversen, Norway (PP20, PP37, PP64, PP66) |
| 14.30–15.30 | Parallel session 4 EUROPAEA Autoinflammatory syndromes Tom Pettersson 14.30–15.00: Autoinflammatory syndromes in the past and in the future • Daniel Kastner 15.00–15.30: Novel autoinflammatory syndromes • Kari Eklund |
Parallel session 5 FENNIA II Pain in arthritis patients Hilde Hammer, Vappu Rantalaiho 14.30–14.55: Neuropathic pain and pain sensitisation in arthritis • Lars Arendt-Nielsen 14.55–15.20: Pain catastrophizing in arthritis patients • Hilde Hammer 15.20–15.30: OP01: Unacceptable, refractory pain despite inflammation control in early rheumatoid arthritis and its relation to treatment strategy: Results from the randomised controlled SWEFOT trial • Jon Lampa |
| 15.30–16.30 | SCR General Assembly | |
| 17.30–18.30 | Opening ceremony including opening lecture What is pre-clinical RA? • Solbritt Rantapää Dahlqvist |
|
| 19.00–20.30 | Helsinki City Reception, Helsinki City Hall | |
| Friday 7 September | |||||
|---|---|---|---|---|---|
| 8.00–9.00 |
Novartis Satellite Symposium EUROPAEA | ||||
| 9.10–10.40 | Parallel session 6 EUROPAEA Systemic lupus erythematosus Søren Jacobsen, Oili Kaipiainen-Seppänen 9.10–9.30: Epidemiology of SLE • Pia Elfving 9.30–9.55: Pathogenesis of SLE • Christopher Sjöwall 9.55–10.25: Modern management of SLE • Søren Jacobsen 10.25–10.40: OP02: Systemic Lupus Erythematosus Subgroups, with Features of Antiphospholipid or Sjögren's Syndrome, differ in molecular signatures and treatment perspectives • Helena Idborg |
Parallel session 7 FENNIA I Genetics and gene expression Peter van der Kraan, Laura Pirilä 9.10–9.40: Epigenetics: DNA methylation and histone acetylation • Steffen Gay 9.40–10.10: Pharmacogenetics in RA • James Bluett 10.10–10.25: OP03: Widespread regulation of gene expression by glucocorticoids in chondrocytes from OA patients as determined by next generation sequencing-based genome wide expression analysis • Antti Pemmari 10.25–10.40: OP04: Shared and unique patterns of DNA methylation in primary Sjögren’s syndrome and systemic lupus erythematosus • Juliana Imgenberg-Kreuz |
|||
| 10.40–11.00 | Coffee break and exhibition | ||||
| 11.00–12.30 | Parallel session 8 EUROPAEA Spondylarthritis and seronegative arthritis Bente Glintborg, Dan Nordström 11.00–11.25: Impact of axial spondylarthritis • Désirée van der Heijde 11.25–11.50: Burden of psoriatic arthritis • Thorvardur Jon Love 11.50–12.15: Long-term outcomes of seronegative arthritis • Kirsi Paalanen 12.15–12.30: OP05: Low rates of major adverse cardiac events, malignancies, and serious infections in subjects with psoriasis and psoriatic arthritis treated with apremilast for ≥156 weeks: pooled analysis from the ESTEEM and PALACE 1-3 phase 3 trials • Arthur Kavanaugh |
Parallel session 9 FENNIA I Innate immunity in arthritis Per-Johan Jakobsson, Johanna Huhtakangas 11.00–11.30: Macrophage phenotypes in arthritis • Irina Udalova 11.30–12.00: Reactive oxygen species in arthritis • Rikard Holmdahl 12.00–12.15: OP06: Apremilast specifically inhibits IL-12/IL-23p40 production in human arthritic ex vivo models • Tue Kragstrup 12.15–12.30: OP07: MAP kinase phosphatase-1 (MKP-1) as a target of anti-inflammatory drug treatment: Anti-inflammatory effects of the glucocorticoid dexamethasone are mediated by MKP-1 in murine models • Riina Nieminen |
|||
| 12.30–13.30 | Lunch and exhibition Poster session 2 (posters PP42–76) |
||||
| 13.30–15.00 |
|
||||
| 15.00–15.30 | Coffee break and exhibition Guided poster tours 3 and 4 |
Tour 3: Epidemiology, pain research, Chair Stine Amris, Denmark (PP22, PP24, PP25, PP45) Tour 4: Systemic connective tissue diseases, Chair Christopher Sjöwall, Sweden (PP28, PP57, PP59, PP71) |
|||
| 15.30–17.00 | Parallel session 13 EUROPAEA Myositis and myopathy Lara Dani, Laura Pirilä 15.30–16.00: Differential diagnostics of myopathies in 2018 • Manu Jokela 16.00–16.40: Myositis in 2018. New tools for diagnosis and therapy • Lara Dani 16.40–16.55: OP14: Anti-Jo1 positive myositis patients display a specific IgG Fc-glycan profile which is further enhanced in anti-Jo1 autoantibodies • Catia Cercueira |
Parallel session 14 FENNIA I Osteoarthritis Ali Mobasheri, Jari Arokoski 15.30–16.00: Osteoarthritis - an inflammatory disease • Ali Mobasheri 16.00–16.30: Innate immunity in osteoarthritis, focus on TLRs and NLRs • Michiaki Takagi 16.30–17.00: Novel treatment options for OA • Eeva Moilanen |
|||
| 17.15–18.15 |
Roche Satellite Symposium: Giant Cell Arteritis – A New Era in Treatment EUROPAEA |
Lilly RA Satellite Symposium FENNIA I |
|||
| 19.30–23.00 (TBC) | Congress dinner, Restaurant Saaristo | ||||
| Saturday 8 September | ||
|---|---|---|
| 8.00–9.00 |
Lilly PsA Satellite Symposium EUROPAEA | Pfizer Satellite Symposium FENNIA II |
| 9.15–10.30 | Parallel session 15 EUROPAEA New imaging techniques in rheumatology Espen Haavardsholm, Kirsi Taimen 9.15–9.40: Micro-CT • Ellen Hauge 9.40–10.05: Optical imaging • Mads Ammitzbøll-Danielsen 10.05–10.30: Whole-body MRI • Simon Krabbe |
Parallel session 16 FENNIA I Anti-citrulline and anti-carbamylated protein antibodies in rheumatoid arthritis Gerdur Gröndal, Pia Isomäki 9.15–9.45: The pathogenetic significance of anti-citrulline antibodies • Bence Rethi 9.45–10.15: Anti-carbamylated protein antibodies • Leendert A Trouw 10.15–10.30: OP15: Inflammatory markers in relation to risk factors for cardiovascular disease in the pre-symptomatic phase of rheumatoid arthritis • Heidi Kokkonen |
| 10.30–11.00 | Coffee break and exhibition | |
| 11.00–12.30 | Parallel session 17 EUROPAEA Managing inflammatory arthritis today and tomorrow Helena Andersson, Kari Eklund 11.00–11.25: Update on new and upcoming therapies in RA • Jon Lampa 11.25–11.50: Clinical registries in the Nordic Countries – real world data • Bente Glintborg 11.50–12.15: Can biologic drugs be tapered? • Espen Haavardsholm 12.15–12.30: OP16: The NORD-STAR trial in early RA: A head-to-head comparison of aggressive conventional therapy and three biological therapies and comparison of two de-escalation strategies in patients who respond to treatment • Jon Lampa |
Parallel session 18 FENNIA I Novel contributors in the etiopathogenesis of arthritis Eeva Moilanen 11.00–11.30: Gut microbiota and arthritis • Francesco Ciccia 11.30–11.50: Obesity and adipokines in osteoarthritis • Katriina Vuolteenaho 11.50–12.20: Resolution inducing lipid mediators in arthritis • Per-Johan Jakobsson |
| 12.30–13.00 | Closing session EUROPAEA Rheumatology in 2040 • Lars Kristensen |
|
| 13.00–14.00 | Lunch and exhibition | |